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Breast cancer is a complex disease which is provoked by a multitude of exogenous and
endogenous factors including genetic variations. Recent genome-wide association studies
identified a set of more than 18 novel low penetrant susceptibility loci, however, a limitation
of this powerful approach is the hampered analysis of polymorphisms in DNA sequences
with a high degree of similarity to other genes or pseudo genes. Since this common feature
affects the majority of the highly polymorphic genes encoding phase I and II enzymes the
retrieval of specific genotype data requires adapted amplification methods. With regard to
breast cancer these genes are of certain interest due to their involvement in the metabo-
lism of carcinogens like exogenous genotoxic compounds or steroid hormones.The present
review summarizes the observed effects of functional genetic variants of phase I and II
enzymes in well designed case control studies to shed light on their contribution to breast
cancer risk.
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INTRODUCTION
The implementation of cost effective high-throughput genotyp-
ing methods enables the determination of genotypes at large scale
and fast pace. These improvements are prerequisite of the in depth
investigation of the polygenetic basis of complex diseases. Promi-
nent examples are genome-wide association studies which led to
the identification of novel breast cancer risk factors such as poly-
morphisms in FGFR2, CCND1, TOX3, MAP3K1, LSP1, CDKN2A,
and 2B (Easton et al., 2007; Lambrechts et al., 2012). However, a
shortcoming of this comprehensive approach is the exclusion of
the majority of genes encoding phase I and II enzymes, because
their special genomic architecture hampers the assessment of accu-
rate genotype data. It is necessary to overcome this limitation due
to the fact that functional genetic variations in these genes are
known to alter expression, activity, and stability of the encoded
enzymes causing defective inactivation and excretion of hormones
as well as environmental toxicants (Thompson and Ambrosone,
2000; Reszka et al., 2006). Thus, it is of high relevance to under-
stand the potential impact of these polymorphisms in pathogenic
processes such as carcinogenesis. In addition, these phase I and
II genes play a pivotal role in activation and metabolism of drugs
with the potential to trigger therapy response as well as occurrence
of adverse side effects (Meyer et al., 2012). With respect to breast
cancer pharmacogenetic investigations revealed the impact of a
genetical determined poor metabolizer phenotype of the phase I
enzyme cytochrome P450 (CYP) 2D6 and tamoxifen treatment
outcome (Schroth et al., 2009). This finding has been a matter of
debate due to reports on conflicting results that seem to be based
on inaccurate genotype data (Brauch et al., 2012). Amongst others
this finding underlines the need of specific genotyping methodolo-
gies for genes encoding metabolic enzymes. This review will focus
on studies investigating the role of genetic variants of phase I and
II enzymes in breast cancer risk that used validated genotyping
methods.
BREAST CANCER RISK
Breast cancer is a multifactorial disease and it is known that the
carcinogenic process is affected by several endogenous as well as
exogenous factors (Rebbeck et al., 1997). In this respect, steroid
hormones play a pivotal role (Key et al., 2002b). Epidemiolog-
ical studies indicated an increased breast cancer risk in women
with prolonged exposure to sex hormones, e.g., early menarche
and late menopause (Henderson and Feigelson, 2000; Clemons
and Goss, 2001). Moreover, observational studies revealed the
risk effect of exogenous hormones such as postmenopausal hor-
mone replacement therapy (HRT; Rossouw et al., 2002; Beral and
Million Women Study Collaborators, 2003; Pesch et al., 2005;
Flesch-Janys et al., 2008) and oral contraceptives (Collaborative
Group on Hormonal Factors in Breast Cancer, 1996; Kahlenborn
et al., 2006). The strong correlation between circulation steroid
hormones and breast cancer risk is supported by an observation
of a two-fold increased risk for women with elevated sex hor-
mone levels (Key et al., 2002a; Eliassen et al., 2006). A functional
explanation of these findings comes from in vitro and in vivo stud-
ies that indicated initiation, promotion, and progression of breast
tumorigenesis by estrogens and their metabolites (Nandi et al.,
1995; Yue et al., 2003; Turan et al., 2004). This effect has been
attributed to estrogen-induced gene expression of factors involved
in cell growth and division (Liu and Lin, 2004) as well as geno-
toxic action of metabolic compounds such as 4-hydroxy catechol
estrogens and estrogen-3,4-quinones (Yager and Davidson, 2006).
Moreover, progesterone adds to hormone-induced carcinogenesis
by promotion of estrogen synthesis, estrogen receptor expression,
and cell proliferation (Poutanen et al., 1995; Shyamala et al., 2002;
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Moore et al., 2006; Pawlak and Wiebe, 2007). Beyond hormonal
factors environmental carcinogens, e.g., tobacco smoke, or genetic
factors, e.g., mutations and polymorphisms contribute to breast
cancer susceptibility. A genetic basis of breast cancer has been sug-
gested by family studies indicating a two-fold increased risk in
the first-degree relatives of women with the disease (Collabora-
tive Group on Hormonal Factors in Breast Cancer, 2001). In the
1990s, the two major breast cancer susceptibility genes BRCA1
and BRCA2 were identified (Miki et al., 1994; Wooster et al.,
1995) revealing that harmful mutations in these genes confer to a
cumulative disease risk by age 70 years of 65 and 45%, respectively
(Antoniou et al., 2003). In the following years further genetic fac-
tors with different penetrance and frequency have been described.
As of today less than 5% of familial breast cancer were attributed
to high penetrance breast cancer genes BRCA1, BRCA2, PTEN,
MSH2, STK11, CDH1, and TP53 (Wooster and Weber, 2003; Mal-
one et al., 2006; Walsh et al., 2006) and rare genetic variants at
ATM, CHEK2, BRIP, NBN, RAD50, or PALB2 that jointly con-
fer an approximately two-fold increased risk (Meijers-Heijboer
et al., 2002; The CHEK2 Breast Cancer Case-Control Consortium,
2004; Rahman et al., 2007). Recent genome-wide association stud-
ies revealed strong evidence for more than 18 common breast
cancer susceptibility alleles including FGFR2, CCND1, TNRC9,
MAP3K1, and LSP1 (Cox et al., 2007; Easton et al., 2007; Lam-
brechts et al., 2012). Most of these genes are related to DNA repair,
cell cycle control, apoptosis, cell growth, and division, represent-
ing the most important pathways for the protection of cells against
carcinogenic processes. However, the lack of observed risk asso-
ciations with phase I and II enzymes is potentially based on their
exclusion from genome-wide association studies due to hampered
assay design or poor quality data which is reflected by the low cov-
erage of these genes in current genotyping arrays (Gamazon et al.,
2012).
THE ROLE OF PHASE I AND II ENZYMES IN CARCINOGENESIS
Phase I and II enzymes are of particular interest with respect to
breast cancer due to their involvement in the metabolism of steroid
hormones, chemical carcinogens, and other environmental toxi-
cants (Thompson and Ambrosone, 2000; Reszka et al., 2006). In
phase I reaction substrates usually undergo reduction, oxidation,
or hydroxylation yielding more polar metabolites; the predomi-
nant mediators of this phase are cytochrome P450 (CYP) enzymes
(Guengerich, 1999). In most cases phase I metabolism is followed
by phase II conjugation reactions. During phase II exogenous or
endogenous compounds or their phase I metabolites are conju-
gated to a more polar molecule, a process that usually produces
inactive and water soluble compounds which can be easily excreted
by urine or bile (Smith et al., 1994; Turesky, 2004). Conjugating
enzymes include glutathione-S-transferases (GSTs), sulfotrans-
ferases (SULTs), uridine diphosphate-glucuronosyltransferases
(UGTs),N -acetyltransferases (NATs), and Methyltransferases. The
combined phase I and II metabolism is mainly a detoxification
and elimination process, however, both phases bear the risk of
formation of toxic and highly reactive compounds which can
induce or promote serious health problems such as cancer (Smith
et al., 1994; Windmill et al., 1997). Thus, altered activity of
metabolic enzyme holds the potential to increase the exposure
to carcinogenic compounds and consequently the risk of tumor
formation (Brockstedt et al., 2002).
CHALLENGES OF GENOTYPING
The majority of phase I and II enzymes are encoded by related
genes which constitute gene families and subfamilies depending
on their degree of sequence similarities. This particular genomic
architecture hampers specific genotyping due to the potential
co-amplification of homolog gene sequences. Therefore, the estab-
lishment of accurate analysis methods requires primer selection
by eye inspection, adapted amplification protocols, and verifica-
tion of genotype calls by an independent method (Justenhoven
et al., 2010). An example for the particular need of an appro-
priate genotyping procedure is the analysis of the SULT1A1 638
G>A (rs9282861) polymorphism. The humanSULT1A subfamily
comprises three genes SULT1A1, SULT1A2, and SULT1A3 which
are located in close proximity on the short arm of chromosome
16 and share sequence similarities of more than 90% (Hempel
et al., 2005). Due to these remarkable homologies the selection
of applicable primers which enable specific amplification of the
SULT1A1 638 G>A region is difficult (Figure 1). Usually auto-
matic assay design tools generate inappropriate primers for such
sequences which lead to simultaneous amplification of all mem-
bers of a gene subfamily resulting in incorrect genotype calls due to
abundance of the referent allele (Figure 2A). Valid assays include
the identification of primer binding sites in unique DNA regions
of the respective gene and adapted annealing temperatures, only
such highly selective amplification conditions assure correct geno-
type calls (Figure 2B). Other gene families and subfamilies with
a similar degree of sequence homologies are known for CYP3A,
CYP2C, GST s, as well as NAT s and UGT s (Salinas and Wong,
1999; Gellner et al., 2001; Tukey and Strassburg, 2001; Nelson
et al., 2004; Sim et al., 2008). So far individual assays for some of
these polymorphisms have been established by researchers, e.g., for
CYP3A (Justenhoven et al., 2010; The MARIE-GENICA Consor-
tium on Genetic Susceptibility for Menopausal Hormone Therapy
Related Breast Cancer Risk, 2010), CYP2D6 (Schaeffeler et al.,
2003; Morike et al., 2008), CYP2C19 (Justenhoven et al., 2012),
GST, UGT, and SULT1A (The MARIE-GENICA Consortium on
Genetic Susceptibility for Menopausal Hormone Therapy Related
Breast Cancer Risk, 2010) as well as companies (e.g., Applied
Biosystems and Third Wave Technologies)1,2. Moreover, particu-
lar panels and arrays for the genetic analysis of metabolic enzymes
and transporters have been developed within recent years: the
AmpliChip®CYP P450 Test3, the DMET Plus Panel DNA Chip4,
VeraCode ADME Core Panel5, and the iPLEX ADME PGx Panel6.
These tools were initially launched to support pharmacogenomic
testing in clinical research and diagnostics, however, their coverage
of relevant genes is still incomplete but they provide a convenient
basis for a variety of investigations dealing with diverse health
issues.
1http://www.appliedbiosystems.com
2http://www.twt.com
3http://www.roche.com
4http://www.affimetrix.com
5http://www.illumina.com
6http://www.sequenom.com
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FIGURE 1 | Sequence homologies among the three members of the
SULT1A gene subfamily located at chromosome 16 (NT_010393.16). A
DNA fragment of 484 base pairs shows: the genetic variants SULT1A1 638
G>A (rs9282861, bold) and 667 A>G (rs1801030, bold/italic) as well as 100
base pairs upstream and downstream from these loci. Comparison of the
DNA sequences shows that these genes differ only in a small of number of
nucleotides (marked in gray) indicating sequence similarities of more than
90% between SULT1A1, SULT1A2, and SULT1A3.
FIGURE 2 | Amplification and genotyping of the DNA sequence
comprising the SULT1A1 638 G>A (rs9282861) polymorphism. (A)
The selection of unspecific primer binding sites lead to simultaneous
amplification of SULT1A1, SULT1A2, and SULT1A3 due to their high
degree of sequence homology. This results in accumulation of
amplification products carrying the referent G allele leading to an incorrect
genotype call for rs9282861 (homozygous GG). (B) Selection of primer
binding sites specific for SULT1A1 enables amplification of the rs9282861
sequence region only resulting in correct determination of the genotype
(heterozygous GA).
PHASE I AND II ENZYMES IN ASSOCIATION WITH BREAST
CANCER RISK
Candidate gene approaches provide evidence for a particular role
of metabolic enzymes in breast carcinogenesis. As of yet only
a few studies analyzed the impact of polymorphisms in genes
with high sequence homologies, whereas genes like CYP1A1 and
CYP1B1have been studied intensely (Economopoulos and Sergen-
tanis, 2010; Sergentanis and Economopoulos, 2010). Therefore,
this review focuses on those genes which are usually underrep-
resented in association studies due to technical issues. Literature
search was done by PubMed7 using the key words “breast can-
cer polymorphism phase I,” “breast cancer polymorphism phase
II,” “breast cancer polymorphism CYP” “breast cancer polymor-
phism UGT,” “breast cancer polymorphism SULT,” “breast cancer
7http://www.ncbi.nlm.nih.gov
polymorphism GST,” and “breast cancer polymorphism NAT” in
August 2012. In a next step studies analyzing associations between
the respective polymorphisms and breast cancer risk factors or
breast tumor characteristics were selected on the basis of study
size, i.e., inclusion of more than 500 cases and 500 controls, DNA
extracted from blood, validation of genotyping results by an inde-
pendent method or meta analyses on summary data of at least five
independent studies.
Significant associations, with p< 0.05 or 95% confidence inter-
val not including 1.0, between polymorphic loci in genes encoding
phase I and II enzymes and breast cancer risk are summarized in
Table 1. It has been shown that functional genetic variants of the
CYP2C19 are associated with overall breast cancer risk and HRT-
related breast cancer risk (Gan et al., 2011; Justenhoven et al.,
2012). It is of note that these findings in two independent studies
show similar effects. The variant CYP2C19∗3 (rs57081121) which
lead to a decreased activity of the CYP2C19 has been associated
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Table 2 | Polymorphisms in phase I and II enzymes associated with histo-pathological characteristics of breast tumor.
Subgroup Ethnicity Gene Polymorphism Nucleotide exchange Cases Odds ratio p-Value Reference
Grading Europeans CYP3A43 rs61469810 (*2A) ins>delA G1: 78 G>1:854 1.74 0.010 Justenhoven et al. (2010)
Node status Europeans CYP2C8 rs1058930 (*4) G>C N0:62 N >0: 16 0.18 0.002 Jernstrom et al. (2009)
Studies with more than 500 breast cancer cases and 500 controls were included.
with increased risk in Asians (Gan et al., 2011) and the variant
CYP2C19∗17 (rs12248560) causing an ultra rapid metabolizer
phenotype leads to a decreased HRT-related breast cancer risk in
Europeans (Justenhoven et al., 2012). It is known that CYP2C19
catabolizes estrogens and progesterone (Yamazaki and Shimada,
1997; Cheng et al., 2001; Cribb et al., 2006) and the reported results
suggest that increased metabolic activity of the CYP2C19 lowers
endogenous hormone levels leading to a decreased risk.
The polymorphism rs10235235 located the non-coding region
of the CYP3A locus has been associated with breast cancer risk
in premenopausal women (Johnson et al., 2012). It would be
of particular interest to follow-up this finding in independent
case control collection and functional studies to understand the
observed effect of this variant, because other genetic polymor-
phisms with known functional consequence located in CYP3A4,
CYP3A5, CYP3A7, and CYP3A43 showed no association with
breast cancer risk (The MARIE-GENICA Consortium on Genetic
Susceptibility for Menopausal Hormone Therapy Related Breast
Cancer Risk, 2010).
Two functional genetic variants rs6759892 and rs2070959
which are located in the UGT1A6 have been suggested to affect
overall breast cancer risk. These variants did not show any associa-
tion with hormonal factors (The MARIE-GENICA Consortium on
Genetic Susceptibility for Menopausal Hormone Therapy Related
Breast Cancer Risk, 2010), therefore, the risk effect is may be based
on the role of UGT1A6 in the metabolism of exogenous com-
pounds such as potential carcinogenic drug and food ingredients
(Harding et al., 1988; Bock and Kohle, 2005).
It has been reported that the deletion of theGSTM1 andGSTT1
gene as well as the variant allele of the GSTP1 rs1695 polymor-
phism impact overall breast cancer risk (Steck et al., 2007). Sub-
group analyses showed an association of the GSTT1 gene deletion
and the GSTP1 rs947894 variant with HRT-related breast can-
cer susceptibility (The MARIE-GENICA Consortium on Genetic
Susceptibility for Menopausal Hormone Therapy Related Breast
Cancer Risk, 2010). Moreover, the GSTT1 deletion seems to affect
breast cancer risk in premenopausal women (Van Emburgh et al.,
2008). These observed effects of GST variants on hormone-related
tumorigenesis is may be based on decreased conjugation of geno-
toxic estrogen quinones leading to elevated levels of DNA damage
(Strange et al., 2001; Hachey et al., 2003). In addition, the GSTM1
and GSTT1 deletion as well as the GSTP1 rs1138272 variant, were
suggested to affect tobacco smoke-related breast cancer risk (Terry
and Goodman, 2006) pointing to the potentially critical role of
GSTs in the elimination of exogenous carcinogenic compounds
such as polycyclic aromatic hydrocarbons (Hayes and Pulford,
1995).
The SULT1A1 rs9282861 polymorphism has been associated
with breast cancer risk in postmenopausal women, in particular
with BMI> 25 kg/m2, suggesting a modifying effect of the variant
allele on endogenous sex hormone exposure (Yang et al., 2005;
Jiang et al., 2010).
It has been reported that the variant NAT2 alleles rs1801280,
rs1799929, rs1208, rs1041983, rs1799930, and rs1799931 lead to
an increased smoking-related breast cancer which supports the
hypothesis that slow acetylators may suffer greater exposure to
tobacco carcinogens (Terry and Goodman, 2006).
PHASE I AND II ENZYMES AND BREAST TUMOR
CHARACTERISTICS
Only a few well designed studies investigated the association
between phase I and II enzymes and histo-pathological char-
acteristics of breast tumors (Table 2). One study reported an
association between the rs61469810 polymorphism of CYP3A43
(CYP3A43∗2A) and poorly differentiated breast tumors which
may be explained by a potential contribution of the variant
allele to increased sex hormone levels (Justenhoven et al., 2010).
Another investigation suggested that the rs1058930 polymorphism
of CYP2C8 (CYP2C8∗4) affects lymph node status of breast can-
cer patients (Jernstrom et al., 2009). The variant allele is known
to lower metabolic activity of the encoded enzyme, however, the
authors stated that an impact of the CYP2C9∗2 allele which is
in linkage disequilibrium with CYP2C8∗4 cannot be excluded
(Jernstrom et al., 2009).
CONCLUSION
Genetic variations of phase I and II enzymes alter their activity or
protein biosynthesis leading to defective detoxification and elimi-
nation of carcinogenic compounds. Due to a high degree of DNA
sequence similarity among genes of subfamilies accurate genotyp-
ing requires elaborated methods and exhaustive quality control.
Until now a few well designed studies give insights into the effect
of polymorphisms in metabolic enzymes on breast cancer risk and
point to their crucial action in steroid hormone catabolism. These
finding underline the pivotal role of sex hormones in the regulation
of proliferation, differentiation, and apoptosis as critical pathways
for onset and progression of breast cancer (Schindler et al., 1998;
Gruber et al., 2002; Seeger et al., 2003; Gadducci et al., 2005).
However, a usual short coming is the publication bias related to
findings without significant effect. Taken together, the prediction
of breast cancer risk on polymorphisms of phase I and II enzymes
is in its initial stage and prospective studies including different
ethnic groups are needed in order to achieve genotyping based
reliable risk determination. Recent developments of gene panels
and arrays provide the technical basis for further assessment of
the impact of variations in metabolic genes as well as gene–gene
and gene-exposure interactions. Overall, comprehensive investi-
gations of multiple genetic, endogenous, and exogenous factors
www.frontiersin.org November 2012 | Volume 3 | Article 258 | 5
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will promote the understanding of the molecular mechanisms of
breast carcinogenesis and support the improvement of prevention
strategies.
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